Toxicity of LY303366, an Echinocandin Antifungal, in Mice Pretreated with Glucocorticoids
- 1 February 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (2) , 378-381
- https://doi.org/10.1128/aac.44.2.378-381.2000
Abstract
LY303366 is a semisynthetic derivative of the echinocandin class. During preclinical studies, lethal toxicity was observed in DBA/2 mice pretreated with a cortisone acetate dose followed by treatment with LY303366 at doses ranging from 12.5 to 50 mg/kg of body weight/day given intraperitoneally (i.p.). In the cortisone-treated, uninfected controls, 90% given LY303366 at 50 mg/kg died. Deaths occurred only in steroid-treated mice. In additional experiments, uninfected DBA/2 and CD-1 mice were pretreated with different glucocorticoids. Dosages were adjusted for comparative potency with cortisone and were given at one, two, or five times the equivalent cortisone dosage of 5 mg prior to treatment with LY303366 at 25 mg/kg/day given i.p. Lethal toxicity occurred in DBA/2 mice given hydrocortisone (1× or 2×), triamcinolone (1× or 5×), and cortisone. However, no mice pretreated with 1× or 5× dexamethasone died. In CD-1 mice, deaths occurred only in those given 5× triamcinolone; three of five died 2 days after the cessation of 10 days of LY303366 treatment. The causes of the deaths and why inbred DBA/2 mice are more sensitive than outbred CD-1 mice to the combined lethal effects of LY303366 and some glucocorticoids could not be determined histologically and remain unexplained. This is the first report of this toxicity of combination glucocorticoids and LY303366. Whether a similar toxicity might apply to the other compounds in the echinocandin class of antifungals and the species specificity require additional study. In addition, the clinical relevance of these observations in steroid-treated patients to the clinical safety of LY303366 and other echinocandins needs to be determined.Keywords
This publication has 10 references indexed in Scilit:
- Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic RabbitsAntimicrobial Agents and Chemotherapy, 1998
- Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal AgentsAntimicrobial Agents and Chemotherapy, 1998
- Efficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive AspergillosisAntimicrobial Agents and Chemotherapy, 1998
- In Vitro Activity of Two Echinocandin Derivatives, LY303366 and MK-0991 (L-743,792), Against Clinical Isolates of Aspergillus, Fusarium, Rhizopus, and Other Filamentous FungiDiagnostic Microbiology and Infectious Disease, 1998
- Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 1997
- In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolatesAntimicrobial Agents and Chemotherapy, 1997
- Semisynthetic Chemical Modification of the Antifungal Lipopeptide Echinocandin B (ECB): Structure-Activity Studies of the Lipophilic and Geometric Parameters of Polyarylated Acyl Analogs of ECBJournal of Medicinal Chemistry, 1995
- Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1994
- Development of heart and aortic lesions in DBA/2NCrj miceLaboratory Animals, 1986
- Spontaneous calcification in hearts of DBA miceThe Anatomical Record, 1969